Challenges in trials evaluating statins in heart failure

Archives of Medical Science

Volumn 3, Issue 4 SUPPL. A, 2007, Pages

  Krum, Henry ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Clinical trials; Heart failure; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; LISINOPRIL; ROSUVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ATHEROSCLEROSIS; CARDIOMYOPATHY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG MEGADOSE; HEART FAILURE; HEART INFARCTION; HUMAN; PATHOGENESIS; PROPHYLAXIS; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 39449133304     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Teerlink JR. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J Card Fail 2002; 8: 124-7.
2. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-40.
3. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106: 920-6.
4. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-31.
5. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-61.
6. Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000; 102: 611-6.
7. Martin JH, Krum H. Statins and clinical outcomes in heart failure. Clin Sci (Lond) 2007; 113: 119-27.
8. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000; 356: 930-3.
9. Rauchhaus M, Clark A, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003; 42: 1933-40.
10. Hargreaves IP, Duncan AJ, Heales SJ, Land JM. The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications. Drug Saf 2005; 28: 659-76.
11. Krum H, Ashton E, Reid C, et al. Double-blind, randomized placebo-controlled, parallel-group, multi center, phase III study to assess the impact of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Failure 2007; 13: 1-7.
12. Tavazzi L, Tognoni G, Franzosi MG, et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004; 6: 635-41.
13. Krum H, Ruschitzka F. 'Class effect' amongst cardiac drugs: term of convenience or pharmacological reality? Int J Clin Pract 2006; 60: 2-5.
14. Sola S, Mir M, Lerakis S, Tandon N, Khan B. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in non-ischaemic heart failure. J Am Coll Cardiol 2006; 47: 332-7.
15. Node K, Fujita M, Kitakaze M, Hori M, Liao J. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003; 108: 839-43.
16. Zacá V, Rastogi S, Imai M, et al. Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 2007; 50: 551-7.
17. Bleske BE, Nicklas JM, Bard RL, et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischaemic cardiomyopathy and average low density lipoprotein level. J Am Coll Cardiol 2006; 47: 338-41.
18. Khush KK, Waters DD, Bittner V, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007; 115: 576-83.